Targovax AS has reached primary endpoint for the ongoing phase I/II clinical trial CT TG01-01
More information on the event https://www.fiban.org/European-Business-Angel-Conference-Helsinki.
More information on the event https://www.fiban.org/European-Business-Angel-Conference-Helsinki.